

Depression and anxiety disorders in Spondyloarthritis patients on biologic therapy registered in Reuma.pt: prevalence, role of disease-related factors and influence of biologic therapy

Prevalence of anxiety and depressive disorders had been reported to be higher in patients with chronic conditions than in global population. In inflammatory rheumatic diseases like Spondyloarthritis (SpA), inflammation had been suggested to have a role in the pathogenesis of these mental disorders. If so, blocking the inflammation pathways could be a weapon not only to treat the disease but also to improve depressive and anxious symptoms. The study we designed aims to assess the prevalence of depression and anxiety in patients with SpA at the moment of first biologic Disease-Modifying AntiRheumatic Drug (bDMARD) prescription and to assess the effect of bDMARD on anxious and depressive symptoms.

Research team: Nathalie Madeira, Helena Santos, Cândida Silva, Luís Cunha Miranda and representatives of other Centers who will accept to collaborate.